An intergenic region ALK fusion identified by DNA sequencing and validated by IHC in an early-stage lung adenocarcinoma.
Adenocarcinoma of Lung
/ genetics
Anaplastic Lymphoma Kinase
/ analysis
DNA, Intergenic
/ genetics
High-Throughput Nucleotide Sequencing
Humans
Immunohistochemistry
Lung Neoplasms
/ genetics
Male
MicroRNAs
/ analysis
Middle Aged
Neoplasm Staging
Oncogene Proteins, Fusion
/ analysis
Sequence Analysis, DNA
Validation Studies as Topic
Intergenic fusion
MIR548AD-ALK
NGS
NSCLC
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
14
10
2020
accepted:
10
01
2021
pubmed:
6
2
2021
medline:
26
5
2021
entrez:
5
2
2021
Statut:
ppublish
Résumé
Anaplastic Lymphoma Kinase (ALK) fusion is an important driver mutation and therapeutic target. At present, more than 20 fusion partners for ALK in NSCLC have been reported. However, ALK intergenic-breakpoint fusions confound fusion detection and target treatment. Here, we reported a 53-year-old early-stage lung adenocarcinoma patient with an MIR548AD-ALK intergenic fusion and was verified by immunohistochemical staining (IHC). In early-stage NSCLC, compared with other clinically relevant driver mutations, ALK fusions were associated with a trend toward poor disease outcomes. Our Next-generation sequencing (NGS) and IHC results may indicate the prognosis of the patient and provide an alternative treatment option for postoperative recurrence.
Identifiants
pubmed: 33544200
doi: 10.1007/s00432-021-03526-5
pii: 10.1007/s00432-021-03526-5
doi:
Substances chimiques
DNA, Intergenic
0
MIRN548 microRNA, human
0
MicroRNAs
0
Oncogene Proteins, Fusion
0
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Types de publication
Case Reports
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
1865-1867Références
Chaft JE, Dagogo-Jack I, Santini FC, Eng J, Yeap BY, Izar B, Chin E, Jones DR, Kris MG, Shaw AT, Gainor JF (2018) Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer 122:67–71. https://doi.org/10.1016/j.lungcan.2018.05.020
doi: 10.1016/j.lungcan.2018.05.020
pubmed: 30032847
pmcid: 6062851
Li P, Gao Q, Jiang X, Zhan Z, Yan Q, Li Z, Huang C (2019) Comparison of clinicopathological features and prognosis between ALK rearrangements and EGFR mutations in surgically resected early-stage lung adenocarcinoma. J Cancer 10(1):61–71. https://doi.org/10.7150/jca.26947
doi: 10.7150/jca.26947
pubmed: 30662526
pmcid: 6329857
Li W, Liu Y, Li W, Chen L, Ying J (2020) Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in NSCLC. J Thora Oncol 15(7):1223–1231. https://doi.org/10.1016/j.jtho.2020.02.023
doi: 10.1016/j.jtho.2020.02.023
Lin C, Shi X, Yang S, Zhao J, He Q, Jin Y, Yu X (2019) Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer. Lung Cancer 131:62–68. https://doi.org/10.1016/j.lungcan.2019.03.018
doi: 10.1016/j.lungcan.2019.03.018
pubmed: 31027700
Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L (2018) Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat Rev Clin Oncol 15:694–708. https://doi.org/10.1038/s41571-018-0081-4
doi: 10.1038/s41571-018-0081-4
pubmed: 30108370
Tian P, Liu Y, Zeng H, Tang Y, Lizaso A, Ye J, Shao L, Li Y (2020) Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes. J Cancer Res Clin Oncol 146(4):935–944. https://doi.org/10.1007/s00432-019-03116-6
doi: 10.1007/s00432-019-03116-6
pubmed: 31894386
Zhang J, Zou C, Zhou C, Luo Y, He Q, Sun Y, Zhou J, Ke Z (2020) A Novel Linc00308/D21S2088E intergenic region ALK fusion and its enduring clinical responses to crizotinib. J Thora Oncol 15(6):1073–1077. https://doi.org/10.1016/j.jtho.2020.03.009
doi: 10.1016/j.jtho.2020.03.009